文献速递前列腺癌

联合Proclarix与磁共振成像准确诊断前列腺癌

Accurate diagnosis of prostate cancer by combining Proclarix with magnetic resonance imaging.
PubMed 文献 · BJU Int · 2023-03-21

研究纳入721例接受mpMRI及活检的男性,采用UCL队列(n=159)训练Proclarix-MRI模型并在Vall d'Hebron队列(n=562)验证。验证队列对临床显著前列腺癌的敏感性90%、阴性预测值90%、阳性预测值66%;模型特异度68%显著优于MRI-ERSPC风险评分51%、单独Proclarix 27%及单独mpMRI 28%(P<0.001)。在PI-RADS 3亚组中Proclarix特异度25%优于PSA密度13%(P=0.004),敏感性均为100%。

要点

  • Proclarix-MRI模型验证队列敏感性90%、阴性预测值90%、阳性预测值66%。
  • 模型特异度68%显著优于MRI-ERSPC评分51%、Proclarix 27%和mpMRI 28%(P<0.001)。
  • PI-RADS 3亚组Proclarix特异度25%优于PSA密度13%(P=0.004),敏感性均100%。

核心结论

  • Proclarix与mpMRI及前列腺体积联合可可靠预测临床显著前列腺癌并排除无或惰性癌男性。
  • 该联合可减少三分之二不必要的活检。
  • Proclarix可高置信度用于PI-RADS 3不确定评分男性可靠检出临床显著前列腺癌。
  • 尽管结果令人鼓舞,仍需进一步验证。

研究设计与样本

  • 研究纳入721例接受mpMRI后活检的男性,血样来自伦敦大学学院医院和巴塞罗那Vall d'Hebron大学医院,样本盲法检测。
  • Proclarix-MRI模型结合前列腺体积、Proclarix和mpMRI结果,用UCL队列(n=159)训练,在Vall d'Hebron队列(n=562)验证。
  • 诊断性能与活检结果相关,并与现有临床参数和风险计算器比较。

主要发现

  • 验证队列中Proclarix-MRI模型临床性能与训练队列无显著差异,对临床显著前列腺癌敏感性90%、阴性预测值90%、阳性预测值66%。
  • Proclarix-MRI评分特异度68%显著(P<0.001)优于MRI-ERSPC风险评分51%、单独Proclarix 27%或单独mpMRI 28%。
  • 在MRI PI-RADS评分3亚组中,Proclarix在100%敏感性下特异度25%优于前列腺特异抗原密度13%(P=0.004)。

关键数值与推荐

  • 临床显著前列腺癌定义为国际泌尿病理学会分级组≥2。
  • 验证队列Proclarix-MRI模型敏感性90%、阴性预测值90%、阳性预测值66%、特异度68%。
  • MRI-ERSPC风险评分特异度51%、单独Proclarix特异度27%、单独mpMRI特异度28%,与Proclarix-MRI评分68%比较P<0.001。
  • PI-RADS 3亚组Proclarix特异度25% vs PSA密度13%(P=0.004),两者敏感性均为100%。

临床怎么用

  • 作者结论认为Proclarix与mpMRI及前列腺体积联合可可靠预测临床显著前列腺癌并排除无或惰性癌男性。
  • 作者结论认为该联合可实现减少三分之二不必要活检。
  • 作者结论认为Proclarix可高置信度用于PI-RADS 3不确定评分男性可靠检出临床显著前列腺癌。

局限性

  • 原文结论指出尽管结果令人鼓舞,仍需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To assess of the clinical performance of Proclarix® (a novel Conformité Européenne [CE]-marked biomarker test aiding in the identification of clinically significant prostate cancer [csPCa]) alone or in combination with multiparametric magnetic resonance imaging (mpMRI) to predict csPCa (International Society of Urological Pathology Grade Group ≥2). PATIENTS AND METHODS: The study included blood samples from 721 men undergoing mpMRI followed by biopsy at University College London, London, and Vall d'Hebron University Hospital, Barcelona. Samples were tested blindly. The Proclarix-MRI model combining prostate volume, Proclarix and mpMRI results was trained using the UCL cohort (n = 159) and validated in the Vall d'Hebron cohort (n = 562). Its diagnostic performance was established in correlation to biopsy outcome and compared to available clinical parameters and risk calculators. RESULTS: Clinical performance of the Proclarix-MRI model in the validation cohort did not significantly differ from the training cohort and resulted in a sensitivity for csPCa of 90%, 90% negative predictive value and 66% positive predictive value. The Proclarix-MRI score's specificity (68%) was significantly (P < 0.001) better than the MRI-European Randomized study of Screening for Prostate Cancer risk score (51%), Proclarix (27%) or mpMRI (28%) alone. In addition, Proclarix by itself was found to be useful in the MRI Prostate Imaging-Reporting and Data System (PI-RADS) score 3 subgroup by outperforming prostate-specific antigen density in terms of specificity (25% vs 13%, P = 0.004) at 100% sensitivity. CONCLUSION: When combined with mpMRI and prostate volume, Proclarix reliably predicted csPCa and ruled out men with no or indolent cancer. A large reduction of two thirds of unneeded biopsies was achieved. Proclarix can further be used with high confidence to reliably detect csPCa in men with an indeterminate PI-RADS score 3 mpMRI. Despite these encouraging results, further validation is needed.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Morote J, Pye H, Campistol M, et al. Accurate diagnosis of prostate cancer by combining Proclarix with magnetic resonance imaging. BJU Int. 2023. PMID: 36855895. doi:10.1111/bju.15998

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。